Figure 3.

Three-month variations in sNfL (A) and sGFAP (B) levels induced by ocrelizumab treatment. sNfL and sGFAP levels measured before (0M) and at 3 (3M), 6 (6M), 9 (9M), and 12 (12M) months of ocrelizumab initiation. Abbreviations: sNfL, serum neurofilament light chains; sGFAP, serum glial fibrillary acidic protein; NEDA-3, patients free of disease activity at 12 months of ocrelizumab initiation (n = 85); INFL, patients with new relapses and/or radiological activity during follow-up (n = 20); PIRA, patients who had confirmed disability progression in the absence of relapses or new MRI activity at 12 months of ocrelizumab initiation (n = 10).